Non-Hodgkin lymphoma after pediatric kidney transplantation.
Kidney transplantation
Management
Non-Hodgkin lymphoma (NHL)
Risk factors
Journal
Pediatric nephrology (Berlin, Germany)
ISSN: 1432-198X
Titre abrégé: Pediatr Nephrol
Pays: Germany
ID NLM: 8708728
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
16
04
2021
accepted:
24
06
2021
revised:
27
05
2021
pubmed:
12
10
2021
medline:
1
7
2022
entrez:
11
10
2021
Statut:
ppublish
Résumé
Non-Hodgkin lymphoma (NHL) that develops after kidney transplantation belongs to post-transplant lymphoproliferative disorders (PTLD) occurring with an incidence of 2-3%. Most pediatric cases are related to primary infection with Epstein-Barr virus (EBV), able to transform and immortalize B cells and widely proliferate due to the lack of relevant control of cytotoxic T cells in patients receiving post-transplant immunosuppression. NHL may develop as a systemic disease or as a localized lesion. The clinical pattern is variable, from non-symptomatic to fulminating disease. Young age of transplant recipient, seronegative EBV status at transplantation, and EBV mismatch between donor and recipient (D+/R-) are regarded as risk factors. Immunosuppression impacts the development of both early and late NHLs. Specific surveillance protocols, including monitoring of EBV viral load, are used in patients at risk; however, detailed histopathology diagnosis and evaluation of malignancy staging is crucial for therapeutic decisions. Minimizing of immunosuppression is a primary management, followed by the use of rituximab in B-cell NHLs. Specific chemotherapeutic protocols, adjusted to lymphoma classification and staging, are used in advanced NHLs. Radiotherapy and/or surgical removal of malignant lesions is limited to the most severe cases. Outcome is variable, depending on risk factors and timing of diagnosis, however is positive in pediatric patients in terms of graft function and patient survival. Kidney re-transplantation is possible in survivors who lost the primary graft due to chronic rejection, however may be performed after at least 2-3 years of waiting time, careful verification of malignancy-free status, and gaining immunity against EBV.
Identifiants
pubmed: 34633534
doi: 10.1007/s00467-021-05205-6
pii: 10.1007/s00467-021-05205-6
pmc: PMC9239945
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1759-1773Informations de copyright
© 2021. The Author(s).
Références
Swerdlow SH, Webber SA, Ferry JA (2017) Post-transplant lymphoproliferative Disorders. In: Swerdlow S, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (eds) WHO Classification of Tumours of Haematopoietic and Lumphoid Tissue (revised), 4th edn. Lyon, AARC, pp 453–464
Mynarek M, Hussein K, Kreipe H, Maecker-Kolhoff B (2014) Malignancies after pediatric kidney transplantation: more than PTLD? Pediatr Nephrol 29:1517–1528. https://doi.org/10.1007/s00467-013-2622-5
doi: 10.1007/s00467-013-2622-5
pubmed: 24061645
Montanari F, Orjuela-Grimm M (2021) Joining Efforts for PTLD: Lessons Learned from Comparing the Approach and Treatment Strategies Across the Pediatric and Adult Age Spectra. Curr Hematol Malig Rep 16(1):52-60. https://doi.org/10.1007/s11899-021-00606-8
Abbas F, El Kossi M, Shaheen IS, Sharma A, Halawa A (2020) Post-transplantation lymphoproliferative disorders: Current concepts and future therapeutic approaches. World J Transplant 10:29–46. https://doi.org/10.5500/wjt.v10.i2.29
doi: 10.5500/wjt.v10.i2.29
pubmed: 32226769
pmcid: 7093305
Yanik EL, Smith JM, Shiels MS, Clarke CA, Lynch CF, Kahn AR, Koch L, Karen S, Pawlish KS, Engels EA (2017) Cancer Risk After Pediatric Solid Organ Transplantation. Pediatrics 139:e20163893. https://doi.org/10.1542/peds.2016-3893
doi: 10.1542/peds.2016-3893
pubmed: 28557749
pmcid: 5404730
Kitchlu A, Dixon S, Dirk JS, Chanchlani R, Vasilevska-Ristovska J, Borges K, Dipchand AI, Ng VL, Hebert D, Solomon M, Michael Paterson J, Gupta S, Joseph Kim S, Nathan PC, Parekh RS (2019) elevated risk of cancer after solid organ transplant in childhood: a population-based cohort study. Transplantation 103:588–596. https://doi.org/10.1097/TP.0000000000002378
doi: 10.1097/TP.0000000000002378
pubmed: 30048393
Minard-Colin V, Brugières L, Reiter A, Cairo MS, Gross TG, Woessmann W, Burkhardt B, Sandlund JT, Williams D, Pillon M, Horibe K, Auperin A, Le Deley MC, Zimmerman M, Perkins SL, Raphael M, Lamant L, Klapper W, Mussolin L, Poirel HA, Macintyre E, Damm-Welk C, Rosolen A, Patte C (2015) Non-Hodgkin lymphoma in children and adolescents: progress through effective collaboration, current knowledge, and challenges ahead. J Clin Oncol 33:2963–2974. https://doi.org/10.1200/JCO.2014.59.5827
doi: 10.1200/JCO.2014.59.5827
pubmed: 26304908
pmcid: 4979194
Debray D, Baudouin V, Lacaille F, Charbit M, Rive C, Harambat J, Iserin F, Di Filippo S, Guyot C, Pediatric Transplantation Working Group of the French Speaking Society of Transplantation (2009) De novo malignancy after solid organ transplantation in children. Transplant Proc 41:674–675. https://doi.org/10.1016/j.transproceed.2008.12.020
doi: 10.1016/j.transproceed.2008.12.020
pubmed: 19328954
Koukourgianni F, Harambat J, Ranchin B, Euvrard S, Bouvier R, Liutkus A, Cochat P (2010) Malignancy incidence after renal transplantation in children: a 20-year single-centre experience. Nephrol Dial Transplant 25:611–616. https://doi.org/10.1093/ndt/gfp497
doi: 10.1093/ndt/gfp497
pubmed: 19820249
Simard JF, Baecklund E, Kinch A, Brattström C, Ingvar A, Molin D, Adami J, Fernberg P, Wilczek H, Ekbom A, Smedby KE (2011) Pediatric organ transplantation and risk of premalignant and malignant tumors in Sweden. Am J Transplant 11:146–151. https://doi.org/10.1111/j.1600-6143.2010.03367.x
doi: 10.1111/j.1600-6143.2010.03367.x
pubmed: 21199354
Yanik EL, Shiels MS, Smith JM, Clarke CA, Lynch CF, Kahn AR, Koch L, Pawlish JS, Engels EA (2017) Contribution of solid organ transplant recipients to the pediatric non-Hodgkin lymphoma burden in the United States. Cancer 123:4663–4671. https://doi.org/10.1002/cncr.30923
doi: 10.1002/cncr.30923
pubmed: 28759103
Füreder A, Kropshofer G, Benesch M, Dworzak M, Greil S, Huber WD, Hubmann H, Lawitschka A, Mann G, Michel-Behnke I, Müller-Sacherer T, Pichler H, Simonitsch-Klupp I, Schwinger W, Szepfalusi Z, Crazzolara R, Attarbaschi A; Austrian Society of Pediatric Hematology and Oncology (2021) Characteristics, management, and outcome of pediatric patients with post-transplant lymphoproliferative disease-a 20 years’ experience from Austria. Cancer Rep (Hoboken) e1375. https://doi.org/10.1002/cnr2.1375
Allen UD, Preiksaitis J, AST Infectious Diseases Community of Practice (2019) Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transpl 33:e13652. https://doi.org/10.1111/ctr.13652
doi: 10.1111/ctr.13652
Caillard S, Lamy FX, Quelen C, Danta J, Lebranchu Y, Lang P, Velten M, Moulin B, French Transplant Centers (2012) Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: report of the French registry and analysis of subgroups of lymphomas. Am J Transplant 12(3):682–693. https://doi.org/10.1111/j.1600-6143.2011.03896
doi: 10.1111/j.1600-6143.2011.03896
pubmed: 22226336
Schober T, Framke T, Kreipe H, Schulz TF, Großhennig A, Hussein K, Baumann U, Pape L, Schubert S, Wingen AM, Jack T, Koch A, Klein C, Maecker-Kolhoff B (2013) Characteristics of early and late PTLD development in pediatric solid organ transplant recipients. Transplantation 95:240–246. https://doi.org/10.1097/TP.0b013e318277e344
doi: 10.1097/TP.0b013e318277e344
pubmed: 23222898
Rosolen A, Perkins SL, Pinkerton CR, Guillerman RP, Sandlund JT, Patte C, Alfred Reiter A, Cairo MS (2015) Revised International Pediatric Non-Hodgkin Lymphoma Staging System. J Clin Oncol 33:2112–2118. https://doi.org/10.1200/JCO.2014.59.7203
doi: 10.1200/JCO.2014.59.7203
pubmed: 25940716
pmcid: 4461808
L'Huillier AG, Dipchand AI, Ng VL, Hebert D, Avitzur Y, Solomon M, Ngan B-Y, Stephens D, Punnett AS, Barton M, Allen UD (2019) Posttransplant lymphoproliferative disorder in pediatric patients: survival rates according to primary sites of occurrence and a proposed clinical categorization. Am J Transplant 19:2764–2774. https://doi.org/10.1111/ajt.15358
doi: 10.1111/ajt.15358
pubmed: 30884098
Mahale P, Shiels MS, Lynch CF, Engels EA (2018) Incidence and outcomes of primary central nervous system lymphoma in solid organ transplant recipients. Am J Transplant 18:453–461. https://doi.org/10.1111/ajt.14465
doi: 10.1111/ajt.14465
pubmed: 28805292
Maecker B, Jack T, Zimmermann M, Abdul-Khaliq H, Burdelski M, Fuchs A, Hoyer P, Koepf S, Kraemer U, Laube GF, Müller-Wiefel DE, Netz H, Pohl M, Toenshoff B, Wagner HJ, Wallot M, Welte K, Melter M, Offner G, Klein C (2007) CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation. J Clin Oncol 25:4902–4908. https://doi.org/10.1200/JCO.2006.10.2392
doi: 10.1200/JCO.2006.10.2392
pubmed: 17971586
Taj MM, Maecker-Kolhoff B, Ling R, Bomken S, Burkhardt B, Chiang AKS, Csoka M, Füreder A, Haouy S, Lazic J, Miakova N, Minard-Colin V, Turner SD, Uyttebroeck A, Attarbaschi A, European Intergroup for Childhood Non-Hodgkin’s Lymphoma (EICNHL), the international Berlin-Frankfurt-Münster (i-BFM) Study Group (2021) Primary post-transplant lymphoproliferative disorder of the central nervous system: characteristics, management and outcome in 25 paediatric patients. Br J Haematol. https://doi.org/10.1111/bjh.17398
Cohen JI (2000) N Engl J Med 343:481–492. https://doi.org/10.1056/NEJM200008173430707
doi: 10.1056/NEJM200008173430707
pubmed: 10944566
Opelz G, Daniel V, Naujokat C, Döhler B (2009) Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma. Transplantation 88:962–967. https://doi.org/10.1097/TP.0b013e3181b9692d
doi: 10.1097/TP.0b013e3181b9692d
pubmed: 19855238
Sampaio MS, Cho YW, Shah T, Bunnapradist S, Hutchinson IV (2012) Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients. Transplantation 93:73–81. https://doi.org/10.1097/TP.0b013e31823ae7db
doi: 10.1097/TP.0b013e31823ae7db
pubmed: 22129761
Shannon-Lowe C, Rickinson AB, Bell AI (2017) Epstein-Barr virus-associated lymphomas. Philos Trans R Soc Lond Ser B Biol Sci 372:20160271. https://doi.org/10.1098/rstb.2016.0271
doi: 10.1098/rstb.2016.0271
Raab-Traub N (2012) Novel mechanisms of EBV-induced oncogenesis. Curr Opin Virol 2:453–458. https://doi.org/10.1016/j.coviro.2012.07.001
doi: 10.1016/j.coviro.2012.07.001
pubmed: 22858118
pmcid: 4617531
Taylor GS, Long HM, Brooks JM, Rickinson AB, Hislop AD (2015) The immunology of Epstein-Barr virus-induced disease. Annu Rev Immunol 33:787–821. https://doi.org/10.1146/annurev-immunol-032414-112326
doi: 10.1146/annurev-immunol-032414-112326
pubmed: 25706097
Colombini E, Guzzo I, Morolli F, Longo G, Russo C, Lombardi A, Merli P, Russo C, Lombardi L, Murer L, Piga S, Ciofi Degli Atti ML, Locatelli F, Dello Strologo L (2017) Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients. Pediatr Nephrol 32:1433–1442. https://doi.org/10.1007/s00467-017-3627-2
doi: 10.1007/s00467-017-3627-2
pubmed: 28280938
Ladfors SW, Lindahl JK, Hansson S, Brandström P, Andersson R, Jertborn M, Lindh M, Woxenius S, Friman V (2020) Long-lasting chronic high load carriage of Epstein-Barr virus is more common in young pediatric renal transplant recipients. Pediatr Nephrol 35:427–439. https://doi.org/10.1007/s00467-019-04401-9
doi: 10.1007/s00467-019-04401-9
pubmed: 31802220
Hall EC, Engels E, Pfeiffer RM, Segev DL (2015) Association of antibody induction immunosuppression with cancer after kidney transplantation. Transplantation 99:1051–1057. https://doi.org/10.1097/TP.0000000000000449
doi: 10.1097/TP.0000000000000449
pubmed: 25340595
pmcid: 4405385
Martin ST, Powell JT, Patel M, Tsapepas D (2013) Risk of posttransplant lymphoproliferative disorder associated with use of belatacept. Am J Health Syst Pharm 70:1977–1983. https://doi.org/10.2146/ajhp120770
doi: 10.2146/ajhp120770
pubmed: 24173007
van Leeuwen MT, Grulich AE, Webster AC, McCredie MR, Stewart JH, McDonald SP, Amin J, Kaldor JM, Chapman JR, Vajdic CM (2009) Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation. Blood 114:630–637. https://doi.org/10.1182/blood-2009-02-202507
doi: 10.1182/blood-2009-02-202507
pubmed: 19443660
Robson R, Cecka JM, Opelz G, Budde M, Sacks S (2005) Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 5:2954–2960. https://doi.org/10.1111/j.1600-6143.2005.01125.x
doi: 10.1111/j.1600-6143.2005.01125.x
pubmed: 16303010
Nelson BP, Wolniak KL, Evens A, Chenn A, Maddalozzo J, Proytcheva M (2012) Early posttransplant lymphoproliferative disease: clinicopathologic features and correlation with mTOR signaling pathway activation. Am J Clin Pathol 138:568–578. https://doi.org/10.1309/AJCPQYYE04AVGVYI
doi: 10.1309/AJCPQYYE04AVGVYI
pubmed: 23010712
McDonald RA, Smith JM, Ho M, Lindblad R, Ikle D, Grimm P, Wyatt R, Arar M, Liereman D, Bridges N, Harmon W, CCTPT Study Group (2008) Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant 8:984–989. https://doi.org/10.1111/j.1600-6143.2008.02167.x
doi: 10.1111/j.1600-6143.2008.02167.x
pubmed: 18416737
Parker A, Bowles K, Bradley JA, Emery V, Featherstone C, Gupte G, Marcus R, Parameshwar J, Ramsay A, Newstead C, Haemato-oncology Task Force of the British Committee for Standards in Haematology and British Transplantation Society (2010) Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients - BCSH and BTS Guidelines. Br J Haematol 149:675–792. https://doi.org/10.1111/j.1365-2141.2010.08161
doi: 10.1111/j.1365-2141.2010.08161
pubmed: 20408847
Kasztelewicz B, Jankowska I, Pawłowska J, Teisseyre J, Grenda R, Pronicki M, Dzierżanowska-Fangrat K (2011) Epstein-Barr virus DNA load in peripheral blood mononuclear cells and whole blood from pediatric transplant recipients. Transpl Infect Dis 13:471–479. https://doi.org/10.1111/j.1399-3062.2011.00656.x
doi: 10.1111/j.1399-3062.2011.00656.x
pubmed: 21689252
Lau E, Moyers JT, Wang BC, Jeong ISD, Lee J, Liu L, Kim M, Villicana R, Kim B, Mitchell J, Kamal MO, Chen CS, Liu Y, Wang J, Chinnock R, Cao H (2021) Analysis of Post-Transplant Lymphoproliferative Disorder (PTLD) Outcomes with Epstein-Barr Virus (EBV) assessments-a single tertiary referral center experience and review of literature. Cancers (Basel) 13:899. https://doi.org/10.3390/cancers13040899
doi: 10.3390/cancers13040899
Voss S, Cairo MS (2019) Surveillance imaging in pediatric lymphoma. Pediatr Radiol 49:1565–1573. https://doi.org/10.1007/s00247-019-04511-4
doi: 10.1007/s00247-019-04511-4
pubmed: 31620855
Zhang JC, Lan HX, Zhao HJ, Lei YY, Ma L, Xie XY, Lu MD, Wang W (2019) Application of contrast-enhanced ultrasonography in the diagnosis of post-kidney transplant lymphoproliferative disorder in native kidney- a case report. BMC Cancer 19:1135. https://doi.org/10.1186/s12885-019-6355-0
doi: 10.1186/s12885-019-6355-0
pubmed: 31752767
pmcid: 6873515
Montes de Jesus FM, Kwee TC, Nijland M, Kahle XU, Huls G, Dierckx RAJO, van Meerten T, Gheysens O, Dierickx D, Vergote V, Noordzij W, Glaudemans AWJM (2018) Performance of advanced imaging modalities at diagnosis and treatment response evaluation of patients with post-transplant lymphoproliferative disorder: a systematic review and meta-analysis. Crit Rev Oncol Hematol 132:27–38. https://doi.org/10.1016/j.critrevonc.2018.09.007
doi: 10.1016/j.critrevonc.2018.09.007
pubmed: 30447925
Takahara M, Hiraoko S, Okada H (2020) Transabdominal ultrasonographic findings of gastrointestinal lymphoproliferative disease. Intern Med 59:453–454. https://doi.org/10.2169/internalmedicine.3718-19
doi: 10.2169/internalmedicine.3718-19
pubmed: 31534094
Khedmat H, Amini M, Ghamar-Chehreh ME (2014) Colorectal involvement by post-transplant lymphoproliferative disorders: a review of 81 cases. Saudi J Kidney Dis Transpl 25:597–604. https://doi.org/10.4103/1319-2442.132201
doi: 10.4103/1319-2442.132201
pubmed: 24821158
Parker A, Bowles K, Bradley JA, Emery V, Featherstone C, Gupte G, Marcus R, Parameshwar J, Ramsay A, Newstead C, Haemato-oncology Task Force of the British Committee for Standards in Haematology and British Transplantation Society (2010) Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines. Br J Haematol 149:693–705. https://doi.org/10.1111/j.1365-2141.2010.08160
doi: 10.1111/j.1365-2141.2010.08160
pubmed: 20408848
San-Juan R, Manuel O, Hirsch HH, Fernández-Ruiz M, López-Medrano F, Comoli P, Caillard S, Grossi P, Aguado JM, ESGICH PTLD Survey Study Group; European Study Group of Infections in Compromised Hosts (ESGICH) from the European Society of Microbiology and Infectious Diseases (ESCMID) (2015) Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey. Clin Microbiol Infect 21(604):e1–e9. https://doi.org/10.1016/j.cmi.2015.02.002
doi: 10.1016/j.cmi.2015.02.002
Ladfors SW, Lindahl JK, Hansson S, Brandström P, Andersson R, Jertborn M, Lindh M, Woxenius S, Friman V (2020) Long-lasting chronic high load carriage of Epstein-Barr virus is more common in young pediatric renal transplant recipients. Pediatr Nephrol 35:427–439. https://doi.org/10.1007/s00467-019-04401-9
doi: 10.1007/s00467-019-04401-9
pubmed: 31802220
Rabot N, Büchler M, Foucher Y, Moreau A, Debiais C, Machet MC, Kessler M, Morelon E, Thierry A, Legendre C, Rivalan J, Kamar N, Dantal J (2014) CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality. Transpl Int 27:956–965. https://doi.org/10.1111/tri.12375
doi: 10.1111/tri.12375
pubmed: 24964147
Kanzelmeyer NK, Maecker-Kolhoff B, Zierhut H, Lerch C, Verboom M, Haffner D, Pape L (2018) Graft outcomes following diagnosis of post-transplant lymphoproliferative disease in pediatric kidney recipients: a retrospective study. Transpl Int 31:367–376. https://doi.org/10.1111/tri.13071
doi: 10.1111/tri.13071
pubmed: 28906028
Serre JE, Michonneau D, Bachy E, Noël LH, Dubois V, Suberbielle C, Kreis H, Legendre C, Mamzer-Bruneel MF, Morelon E, Thaunat O (2014) Maintaining calcineurin inhibition after the diagnosis of post-transplant lymphoproliferative disorder improves renal graft survival. Kidney Int 85:182–190. https://doi.org/10.1038/ki.2013.25
doi: 10.1038/ki.2013.25
pubmed: 23802193
Dembowska-Bagińska B, Wakulińska A, Daniluk I, Teisseyre J, Jankowska I, Czubkowski P, Grenda R, Jarmużek W, Grajkowska W, Małdyk J, Kaliciński P (2020) Non-Hodgkin lymphoma after liver and kidney transplantation in children. Experience from one center. Adv Clin Exp Med 29:197–202. https://doi.org/10.17219/acem/112605
doi: 10.17219/acem/112605
pubmed: 32154678
Gupta S, Fricker FJ, González-Peralta RP, Slayton WB, Schuler PM, Dharnidharka VR (2010) Post-transplant lymphoproliferative disorder in children: recent outcomes and response to dual rituximab/low-dose chemotherapy combination. Pediatr Transplant 14:896–902. https://doi.org/10.1111/j.1399-3046.2010.01370.x
doi: 10.1111/j.1399-3046.2010.01370.x
pubmed: 20642490
Jagadeesh D, Bruce A, Woda B, Jacqueline Draper J, Andrew M, Evens AM (2012) Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations. Curr Treat Options in Oncol 13:122–136. https://doi.org/10.1007/s11864-011-0177-x
doi: 10.1007/s11864-011-0177-x
Oton A, Wang H, Leleu X, Melhem MF, George D, Lacasce A, Foon KI, Ghobrial IM (2008) Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant. Leuk Lymphoma 49:1738–1744. https://doi.org/10.1080/10428190802239162
doi: 10.1080/10428190802239162
pubmed: 18798108
Dierickx D, Habermann TM (2018) post-transplantation lymphoproliferative disorders in adults. N Engl J Med 378:549–562. https://doi.org/10.1056/NEJMra1702693
doi: 10.1056/NEJMra1702693
pubmed: 29414277
Trappe R, Oertel S, Leblond V, Mollee P, Sender M, Reinke P, Neuhaus R, Lehmkuhl H, Horst HA, Salles G, Morschhauser F, Jaccard A, Lamy T, Leithäuser M, Zimmermann H, Anagnostopoulos I, Raphael M, Riess H, Choquet S, German PTLD Study Group; European PTLD Network (2012) Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 13:196–206. https://doi.org/10.1016/S1470-2045(11)70300-X
doi: 10.1016/S1470-2045(11)70300-X
pubmed: 22173060
Trappe RU, Dierickx D, Zimmermann H, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Reinke P, Verhoef G, Subklewe M, Hüttmann A, Tousseyn T, Salles G, Kliem V, Hauser IA, Tarella C, Van Den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, Choquet S (2017) Response to rituximab induction is a predictive marker in b-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter phase II trial. J Clin Oncol 35:536–543. https://doi.org/10.1200/JCO.2016.69.3564
doi: 10.1200/JCO.2016.69.3564
pubmed: 27992268
Burns DM, Clesham K, Hodgson YA, Fredrick L, Haughton J, Lannon M, Hussein H, Shin JS, Hollows RJ, Robinson L, Byrne C, McNamara C, Vydianath B, Lennard AL, Fields P, Johnson R, Wright J, Fox CP, Cwynarski K, Chaganti S (2020) Real-world outcomes with rituximab-based therapy for posttransplant lymphoproliferative disease arising after solid organ transplant. Transplantation 104:2582–2590. https://doi.org/10.1097/TP.0000000000003183
doi: 10.1097/TP.0000000000003183
pubmed: 33104308
Maecker-Kolhoff B, Beier R, Zimmermann M, Schlegelberger B, Baumann U, Mueller C, Pape L, Reiter A, Rossi C, Schubert S, Toenshoff B, Wingen A-M, Meissner B, Kebelmann-Betzing C, Henze G, Kreipe HH, Klein C (2014) Response-adapted sequential immuno-chemotherapy of post-transplant lymphoproliferative disorders in pediatric solid organ transplant recipients: results from the prospective Ped-PTLD 2005 trial. Blood 124:4468–4468. https://doi.org/10.1182/blood.V124.21.4468.4468
doi: 10.1182/blood.V124.21.4468.4468
Gross TG, Bucuvalas JC, Park JR, Greiner TC, Hinrich SH, Kaufman SS, Langnas AN, McDonald RA, Ryckman FC, Shaw BW, Sudan DL, Lynch JC (2005) Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol 23:6481–6488. https://doi.org/10.1200/JCO.2005.08.074
doi: 10.1200/JCO.2005.08.074
pubmed: 16170157
Gross TG, Orjuela MA, Perkins SL, Park JR, Lynch JC, Cairo MS, Smith LM, Hayashi RJ (2012) Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children’s Oncology Group Report. Am J Transplant 12:3069–3075. https://doi.org/10.1111/j.1600-6143.2012.04206.x
doi: 10.1111/j.1600-6143.2012.04206.x
pubmed: 22883417
pmcid: 3484187
Hyun H, Park E, Cho M, Min SI, Ha J, Kang HJ, Shin HY, Ha IS, Cheong HI, Ahn YH, Kang HG (2019) Post-transplant lymphoproliferative diseases in pediatric kidney allograft recipients with Epstein-Barr virus viremia. J Korean Med Sci 34:e203. https://doi.org/10.3346/jkms.2019.34.e203
doi: 10.3346/jkms.2019.34.e203
pubmed: 31373185
pmcid: 6676002
Perrine SP, Hermine O, Small T, Suarez F, O'Reilly R, Boulad F, Fingeroth J, Askin M, Levy A, Mentzer SJ, Di Nicola M, Gianni AM, Klein C, Horwitz S, Faller DV (2007) A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 109:2571–2578. https://doi.org/10.1182/blood-2006-01-024703
doi: 10.1182/blood-2006-01-024703
pubmed: 17119113
pmcid: 1852196
Funch DP, Walker AM, Schneider G, Ziyadeh NJ, Pescovitz MD (2005) Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 5:2894–2900. https://doi.org/10.1111/j.1600-6143.2005.01115.x
doi: 10.1111/j.1600-6143.2005.01115.x
pubmed: 16303002
Höcker B, Böhm S, Fickenscher H, Küsters U, Schnitzler P, Pohl M, John U, Kemper MJ, Fehrenbach H, Wigger M, Holder M, Schröder M, Feneberg R, Köpf-Shakib S, Tönshoff B (2012) (Val-)Ganciclovir prophylaxis reduces Epstein-Barr virus primary infection in pediatric renal transplantation. Transpl Int 25:723–731. https://doi.org/10.1111/j.1432-2277.2012.01485.x
doi: 10.1111/j.1432-2277.2012.01485.x
pubmed: 22533698
Kampers J, Orjuela-Grimm M, Schober T, Schulz TS, Stiefel M, Klein C, Körholz D, Mauz-Körholz C, Kreipe H, Beier R, Britta Maecker-Kolhoff B (2017) Classical Hodgkin lymphoma-type PTLD after solid organ transplantation in children: a report on 17 patients treated according to subsequent GPOH-HD treatment schedules. Leuk Lymphoma 58:633–638. https://doi.org/10.1080/10428194.2016.1205742
doi: 10.1080/10428194.2016.1205742
pubmed: 27685149
Said-Conti V, Amrolia PJ, Gaze MN, Stoneham S, Sebire N, Shroff R, Marks SD (2013) Successful treatment of central nervous system PTLD with rituximab and cranial radiotherapy. Pediatr Nephrol 28:2053–2056. https://doi.org/10.1007/s00467-013-2499-2493
doi: 10.1007/s00467-013-2499-2493
pubmed: 23743853
Jagadeesh D, Bruce A Woda B, Jacqueline Draper J, Andrew M Evens AM (2012) Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations. Curr Treat Options in Oncol 13:122-136. https://doi.org/10.1007/s11864-011-0177-x
Maecker B, Jack T, Zimmermann M, Abdul-Khaliq H, Burdelski M, Fuchs A, Hoyer P, Koepf S, Kraemer U, Laube GF, Müller-Wiefel DE, h Netz H, Martin Pohl P, Toenshoff B, Wagner HJ, Wallot M, Welte K, Melter M, Offner G, Klein C (2007) CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation. J Clin Oncol 25:4902–4908. https://doi.org/10.1200/JCO.2006.10.2392
doi: 10.1200/JCO.2006.10.2392
pubmed: 17971586
Common Terminology Criteria for Adverse Events (CTCAE) https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_50
Prockop S, Doubrovina E, Suser S, Heller G, Barker J, Dahi P, Perales MA, Papadopoulos E, Sauter C, Castro-Malaspina H, Boulad F, Curran KJ, Giralt S, Gyurkocza B, Hsu KC, Jakubowski A, Hanash AM, Kernan NA, Kobos R, Koehne G, Landau H, Ponce D, Spitzer B, Young JW, Behr G, Dunphy M, Haque S, Teruya-Feldstein J, Arcila M, Moung C, Hsu S, Hasan A, O'Reilly RJ (2020) Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. J Clin Invest 130:733–747. https://doi.org/10.1172/JCI121127
doi: 10.1172/JCI121127
pubmed: 31689242
pmcid: 6994129
Ricciardelli I, Brewin J, Lugthart G, Albon SJ, Pule M, Amrolia PJ (2013) Rapid generation of EBV-specific cytotoxic T lymphocytes resistant to calcineurin inhibitors for adoptive immunotherapy. Am J Transplant 13:3244–3252. https://doi.org/10.1111/ajt.12475
doi: 10.1111/ajt.12475
pubmed: 24266973
Rouphael B, Lankireddy S, Lazaryan A, Kukla A, Ibrahim HN, Matas AJ, Naim Issa N (2016) Outcomes of kidney retransplantation in recipients with prior post-transplant lymphoproliferative disorder. Clin Transpl 30:60–65. https://doi.org/10.1111/ctr.12659
doi: 10.1111/ctr.12659
Johnson SR, Cherikh WS, Kauffman HM, Pavlakis M, Hanto DW (2006) Retransplantation after post-transplant lymphoproliferative disorders: an OPTN/UNOS database analysis. Am J Transplant 6:2743–2749. https://doi.org/10.1111/j.1600-6143.2006.01543.x
doi: 10.1111/j.1600-6143.2006.01543.x
pubmed: 17049062
Caillard S, Cellot E, Dantal J, Thaunat O, Provot F, Janbon B, Buchler M, Anglicheau D, Merville P, Lang P, Frimat L, Colosio C, Alamartine E, Kamar N, Heng AE, Durrbach A, Moal V, Rivalan J, Etienne I, Peraldi MN, Moreau A, Moulin B; French PTLD Registry (2017) A French cohort study of kidney retransplantation after post-transplant lymphoproliferative disorders. Clin J Am Soc Nephrol 12:1663-1670. https://doi.org/10.2215/CJN.03790417